A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2026

Conditions
Acute Lymphoblastic Leukemia
Interventions
DRUG

Navitoclax

P.O 50mg QD Q28 days for 2 cycles pre-transplant Up to 50mg QD Q28 days maintnance post-transplant based on MTD

DRUG

Venetoclax

P.O 400mg QD Q28 days for 2 cycles pre-transplant Up to 400mg QD Q28 days maintnance post-transplant based on MTD

Trial Locations (6)

49100

Rabin Medical Center, Petah Tikva

52621

Sheba Medical Center, Ramat Gan

84101

Soroka Medical Center, Beersheba

3109601

Rambam Health Care Campus, Haifa

6423906

Tel Aviv Sourasky Medical Center, Tel Aviv

9103102

Shaare Zedek Medical Center, Jerusalem

All Listed Sponsors
collaborator

Rabin Medical Center

OTHER

collaborator

Sheba Medical Center

OTHER_GOV

collaborator

Rambam Health Care Campus

OTHER

collaborator

Tel Aviv Medical Center

OTHER

collaborator

Soroka University Medical Center

OTHER

collaborator

Shaare Zedek Medical Center

OTHER

collaborator

Hadassah Medical Organization

OTHER

lead

Israeli Medical Association

OTHER